You are here: Industry Insights > AstraZeneca

News List

FDA approves new dosing option for AZ’s Imfinzi pharmatimes
November 25, 2020
The US Food and Drug Administration (FDA) has approved AstraZeneca’s (AZ) checkpoint inhibitor Imfinzi for an additional dosing option.
AstraZeneca COVID-19 Vaccine Meets Primary Efficacy Endpoint americanpharmaceuticalreview
November 25, 2020
Positive high-level results from an interim analysis of clinical trials of AstraZeneca’s COVID-19 vaccine, AZD1222, in the UK and Brazil showed the vaccine was highly effective in preventing Coronavirus.
AstraZeneca starts COVID-19 prevention trial for immunocompromised patients europeanpharmaceuticalreview
November 24, 2020
The trial will evaluate if the long-acting monoclonal antibody cocktail, AZD7442, can prevent COVID-19 in patients who cannot be vaccinated.
AZ/Oxford University’s COVID-19 vaccine shows average efficacy of 70% pharmatimes
November 24, 2020
AstraZeneca (AZ) and Oxford University’s COVID-19 vaccine candidate AZD1222 has scored an average efficacy rate of 70% in an interim analysis of phase II/III trials conducted in the UK and Brazil.
AstraZeneca COVID-19 vaccine shows 90 per cent efficacy expresspharma
November 24, 2020
AZD1222, given as a half dose, followed by a full dose at least one month apart, showed vaccine efficacy of 90 per cent while it showed 62 per cent efficacy when given as two full doses at least one month apart.
University of Cambridge Announces Agreement with AstraZeneca, GSK americanpharmaceuticalreview
November 23, 2020
The University of Cambridge announced a five-year agreement with AstraZeneca and GSK to fund the Cambridge Centre for AI in Medicine (CCAIM).
AstraZeneca begins trials on antibody cocktail to prevent COVID-19 expresspharma
November 23, 2020
The prophylactic treatment may prove useful in people whose immune systems are weaker or compromised, and who don’t respond to vaccination.
Tezepelumab Trial Meets Primary Endpoint americanpharmaceuticalreview
November 20, 2020
Amgen and AstraZeneca announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared to placebo in patients with severe ...
COVID-19 vaccine from AstraZeneca produces immune response in elderly expresspharma
November 20, 2020
AstraZeneca and Oxford University’s potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas.
AZ’s Brilinta reduced rate of stroke and death in high-risk subgroup pharmatimes
November 19, 2020
AstraZeneca’s P2Y12 receptor antagonist Brilinta reduced the rate of stroke and death in a prespecified, high-risk subgroup, according to new analysis of the phase III THALES trial.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page